© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 20, 1517-1519,
October 17, 2001
© 2001 Oxford University Press
NEWS |
Rapamycin’s Resurrection: A New Way to Target the Cancer Cell Cycle
CCI-779, a close analogue of rapamycin, has shown activity against a wide range of cancers in preclinical models and in phase I trials, and seven different phase II trials are under way. Some suggest that it may be one of the most promising drugs in the anticancer pipeline.
"I’m excited," said Charles Sawyers, M.D., of the University of California at Los Angeles Jonsson Comprehensive Cancer Center. "It’s a safe drug, it’s very precise in its action, it’s definitely a targeted therapy."
| |||||||||||
The cancer research community is only now becoming aware of CCI-779. But it is hardly new. The parent drug, rapamycin, was discovered 30 years ago, and its activity against cancer was revealed back in the mid-1970s. All of the research on rapamycin,
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Hasty Rapamycin: The Cure for all that Ails J Mol Cell Biol, October 4, 2009; (2009) mjp033v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jimeno, M. A. Rudek, P. Kulesza, W. W. Ma, J. Wheelhouse, A. Howard, Y. Khan, M. Zhao, H. Jacene, W. A. Messersmith, et al. Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors J. Clin. Oncol., September 1, 2008; 26(25): 4172 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Wu, D. C. Birle, and I. F. Tannock Effects of the Mammalian Target of Rapamycin Inhibitor CCI-779 Used Alone or with Chemotherapy on Human Prostate Cancer Cells and Xenografts Cancer Res., April 1, 2005; 65(7): 2825 - 2831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells Blood, February 15, 2005; 105(4): 1669 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Huang, H. Zhu, S. J. Haggarty, D. R. Spring, H. Hwang, F. Jin, M. Snyder, and S. L. Schreiber Finding new components of the target of rapamycin (TOR) signaling network through chemical genetics and proteome chips PNAS, November 23, 2004; 101(47): 16594 - 16599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Rohde, S. Campbell, S. A. Zurita-Martinez, N. S. Cutler, M. Ashe, and M. E. Cardenas TOR Controls Transcriptional and Translational Programs via Sap-Sit4 Protein Phosphatase Signaling Effectors Mol. Cell. Biol., October 1, 2004; 24(19): 8332 - 8341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Raymond, J. Alexandre, S. Faivre, K. Vera, E. Materman, J. Boni, C. Leister, J. Korth-Bradley, A. Hanauske, and J.-P. Armand Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer J. Clin. Oncol., June 15, 2004; 22(12): 2336 - 2347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-C. Noh, W. H. Mondesire, J. Peng, W. Jian, H. Zhang, J. Dong, G. B. Mills, M.-C. Hung, and F. Meric-Bernstam Determinants of Rapamycin Sensitivity in Breast Cancer Cells Clin. Cancer Res., February 1, 2004; 10(3): 1013 - 1023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. I. Brown, J. Fang, K. Alcorn, R. Barr, J. M. Kim, R. Wasserman, and S. A. Grupp Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling PNAS, December 9, 2003; 100(25): 15113 - 15118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Lekmine, S. Uddin, A. Sassano, S. Parmar, S. M. Brachmann, B. Majchrzak, N. Sonenberg, N. Hay, E. N. Fish, and L. C. Platanias Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons J. Biol. Chem., July 18, 2003; 278(30): 27772 - 27780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.D. Sharp, W.-H. Lee, A. Y. Nikitin, A. Flesken-Nikitin, Y. Ikeno, R. Reddick, A. G. Richardson, and J. F. Nelson Minimal effects of dietary restriction on neuroendocrine carcinogenesis in Rb+/- mice Carcinogenesis, February 1, 2003; 24(2): 179 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Decker, S. Hipp, I. Ringshausen, C. Bogner, M. Oelsner, F. Schneller, and C. Peschel Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin Blood, January 1, 2003; 101(1): 278 - 285. [Abstract] [Full Text] [PDF]
|
|